EquityZen Growth Technology Fund LLC - Series 2120
Raised
$228K
Investors
18
Min Invest
$10,017
AltStreet Analysis
·Generated from EDGAR primary sources
EquityZen Growth Technology Fund LLC - Series 2120 is a Delaware-based pooled investment vehicle filed by EquityZen Advisors LLC and Phil Haslett on 2025-09-09. The fund raised $228K from 18 investors with a $10K minimum investment, relying on Rule 506(b) and 3(c)(1) exemptions. It is part of the EquityZen platform, which operates 1,889 related EDGAR entities focused on pre-IPO secondary market access.
This pre-IPO fund follows EquityZen's standard structure: a series-level SPV with 506(b)/3(c)(1) exemptions and a low $10K minimum, democratizing access to private growth-stage technology companies. The $228K raise and 18-investor count reflect a typical small-series vehicle within the platform's multi-thousand-entity portfolio, designed for single-company exposure rather than diversified fund deployment.
Data Flags
EDGAR Filing Data
Form D — Primary Source
View on SEC.govRelated Persons (Form D)
Executive officers, directors, and promoters listed on the SEC Form D filing. Source: SEC.gov.
EquityZen Advisors LLC
Executive Officer, Director · New York, NY
Phil Haslett
Executive Officer, Director · New York, NY
Is this your offering?
Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.
Data Methodology
Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.
